Abbisko Cayman Limited (02256.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 8.30

From 52W high−57.72%

Volume1.80M

Market capHKD 5.18B

P/E (TTM)—

P/S (TTM)45.6x

Div yield—

Key dataSep 18, 2026

Open

HKD 8.30

From 52W high

−57.72%

Volume

1.80M

Market cap

HKD 5.18B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.8x

P/E (TTM)

—

RSI (14)

33.2

MomentumView details →

1D Return

+0.42%

YTD Return

−36.24%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.8x

EV/Sales

24.9x

P/S (TTM)

45.6x

P/B (TTM)

2.0x

ProfitabilityView details →

Gross Margin

98.19%

Net Margin

−479.81%

EBITDA Margin

−523.46%

ROE (TTM)

−21.41%

ROA (TTM)

−17.31%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

−84.28%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+459.32%

EPS CAGR 3Y

+115.25%

EBITDA YoY

—

MomentumView details →

1D Return

+0.42%

YTD Return

−36.24%

1Y Return

−52.46%

RSI (14)

33.2

vs 50D SMA

−16.05%

vs 200D SMA

−29.02%

Capital & dividendView details →

Debt/Equity

0.21x

Current Ratio

4.82x

Quick Ratio

4.82x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.35

EPS Surprise

11.76%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 0.49

Avg Surprise (4Q)

11.76%

Rev Surprise

94.35%

Financials snapshotView financials →

Revenue (TTM)

97.27M

Net Income (TTM)

−466.69M

Op. CF (TTM)

−224.05M

Next earningsMar 18, 2027 →

Latest newsMore news →

Abbisko Therapeutics reported an interim net loss of 193 million RMB for the six months ended June 2026, swinging from a profit of 328 million RMB a year earlier, with revenue down 84.1% to 97.27 million RMB.27d ago

Abbisko Therapeutics entered into a strategic research collaboration and license agreement with Eli Lilly.89d ago

Similar companies

Erasca, Inc.ERAS 博拓生物688767.SH Apellis Pharmaceuticals, Inc.APLS CK Life Sciences Int'l., (Holdings) Inc.00775.HK Dianthus Therapeutics, Inc.DNTH Edgewise Therapeutics, Inc.EWTX Find similar companies →

Latest newsMore news →

Abbisko Therapeutics reported an interim net loss of 193 million RMB for the six months ended June 2026, swinging from a profit of 328 million RMB a year earlier, with revenue down 84.1% to 97.27 million RMB.27d ago Abbisko Therapeutics entered into a strategic research collaboration and license agreement with Eli Lilly.89d ago